Assi R, et al. - Researchers assessed the therapeutic impact of immunosuppressive therapy (IST) plus eltrombopag in patients with aplastic anemia (AA) in this phase 2 trial. They mainly analyzed the overall response rate (ORR) at 3 and 6 months in a total of 38 patients enrolled in this study, including 17 treated with IST alone and 21 treated with additional eltrombopag. The ORR was 74%. The ORR, complete remission rate, and median time to response observed in patients receiving IST plus eltrombopag was found to be similar to those receiving IST alone. Additionally, 91% vs 82% was the observed 2-year overall survival rate in the IST group vs IST plus eltrombopag group, respectively. The addition of eltrombopag resulted in no cumulative toxicities. Overall, similar responses were seen with the addition of eltrombopag to standard IST vs IST alone, and this treatment was well tolerated.